Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F12%3A8090" target="_blank" >RIV/00064203:_____/12:8090 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11130/12:8090

Result on the web

<a href="http://dx.doi.org/10.1007/s00262-011-1149-5" target="_blank" >http://dx.doi.org/10.1007/s00262-011-1149-5</a>

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria

Original language description

We previously demonstrated that autologous dendritic cells that have endocytosed apoptotic bodies of chronic lymphocytic leukemia (CLL) cells (Apo-DC) can stimulate antileukemic T cell responses in vitro. In this phase I study, we vaccinated 15 asymptomatic CLL patients at five time points with Apo-DC administered intradermally either alone (cohort I), or in combination with subcutaneous granulocyte-macrophage-colony-stimulating-factor (GM-CSF) (cohort II) or with GM-CSF and intravenous low-dose cyclophosphamide (cohort III). Aim of the study was to evaluate the safety and immunogenicity of Apo-DC alone or in combination with GM-CSF and low-dose cyclophosphamide in CLL patients. All patients completed the vaccination schedule without dose-limiting toxicity. No objective clinical responses were seen. Vaccine-induced leukemia-specific immune responses were evaluated by IFN-gamma ELISpot and proliferation assays over a 52 weeks observation period and immune response criteria were defined.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

EC - Immunology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2012

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Cancer Immunology Immunotherapy

ISSN

0340-7004

e-ISSN

—

Volume of the periodical

61

Issue of the periodical within the volume

6

Country of publishing house

US - UNITED STATES

Number of pages

15

Pages from-to

865-879

UT code for WoS article

000304621900011

EID of the result in the Scopus database

—